International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 5 , Pages 1383-1390 , 1 April 2009

The Effect of Radiation Dose and Chemotherapy on Overall Survival in 237 Patients With Stage III Non–Small-Cell Lung Cancer

  • Li Wang, M.D. Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • Department of Radiation Oncology, Cancer Center, Fudan University, Shanghai, China
    • ,
  • Candace R. Correa, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Lujun Zhao, M.D. Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • James Hayman, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Gregory P. Kalemkerian, M.D.

      Affiliations

    • Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Susan Lyons, M.D. Ph.D.

      Affiliations

    • Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Kemp Cease, M.D.

      Affiliations

    • Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Dean Brenner, M.D.

      Affiliations

    • Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Feng-Ming Kong, M.D. Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • Department of Radiation Oncology, Veterans Administration Health Center, Ann Arbor, MI
    • Corresponding Author InformationAddress reprint requests to: Feng-Ming (Spring) Kong, M.D., Ph.D., University of Michigan, Department of Radiation Oncology, UH-B2C490, Box 0010, 1500 E. Medical Center Dr., Ann Arbor, MI 48109. Tel: (734) 936-7810; Fax: (734) 763-7370

Received 28 March 2008 ,Revised 29 April 2008 ,Accepted 9 June 2008.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–662007
  2. Furuse K, Fukuoka M, Kawakara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable Stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  3. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a Phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable Stage III NSCLC: RTOG 9410. Proc ASCO. 2003;22:621A;(abstract 2449)
  4. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various radiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 1980;45:2744–2753
  5. Kupelian PA, Komaki R, Allen P. Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36:607–613
  6. Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable Stage I non-small-cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149–154
  7. Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:741–747
  8. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a Phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118–2127
  9. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–333
  10. Chen M, Hayman JA, Ten Haken RK, et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1–3N0 non-small-cell lung cancer: Is low incidence of regional failure due to incidental nodal Radiation?. Int J Radiat Oncol Biol Phys. 2006;64:120–126
  11. Zhao L, West BT, Hayman JA, et al. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:103–110
  12. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a Phase I/II dose escalation trial in non–small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 2003;66:119–126
  13. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable Stage IIIA/B nonsmall cell lung carcinoma. Cancer. 2001;92:1213–1223
  14. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of Stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a Phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348–356
  15. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable Stage IIIA and IIIB non–small-cell lung cancer: A dose-escalation Phase I trial. J Clin Oncol. 2004;22:4341–4350
  16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis. 1987;40:373–383
  17. Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12:539–547
  18. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987;59:1874–1881
  19. Willner J, Baier K, Caragiani E, et al. Dose, volume, and tumor control prediction in primary radiotherapy of nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:382–389
  20. Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for nonsmall-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:49–57
  21. Schwegler N, Gordic J, Ragaz A, et al. Inoperable non-small cell bronchial carcinoma: Macroscopic and microscopic tumor behavior during and after radiotherapy with curative intent. Schweiz Rundsch Med Prax. 1999;88:1825–1836
  22. Machtay M, Swann S, Komaki R, et al. Higher BED is associated with improved local-regional control and survival for NSCLC treated with chemoradiotherapy: An RTOG Analysis. Int J Radiat Oncol Biol Phys. 2005;63(Suppl 1):S40;(abstract 66)
  23. Belani PC, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non small-cell lung cancer: A randomized Phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883–5891
  24. Fournel P, Robinet G, Thomas P, et al. Randomized Phase III trial of sequential chemoradiotherapy compared with concurrent chemo-radiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 study. J Clin Oncol. 2005;23:5910–5917
  25. Zatloukal P, Peruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized Phase II study. Lung Cancer. 2004;46:87–98
  26. Huber RM, Flentje M, Schmidt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable Stage IIIA or IIIB non small-cell lung cancer: Study CTRT 99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol. 2006;24:4397–4404
  27. Vokes EE. Optimal therapy for unresectable Stage III non-small-cell lung cancer. J Clin Oncol. 2005;23:5853–5855
  28. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–1587
  29. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in Stage III non-small-cell lung cancer: An institutional analysis of patients treated under RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002;54:357–364

 Note—An online CME test for this article can be taken at http://asro.astro.org under Continuing Education.

 The study was presented at the 49th annual American Society for Therapeutic Radiology and Oncology (ASTRO) meeting, held October 30, 2007, in Los Angeles. It was named “Best of ASTRO 2007,” and was quoted at the third Annual Mid-Atlantic ASTRO Review Course on January 10, 2008, at the University of Maryland.

 Conflict of interest: none.

PII: S0360-3016(08)03057-5

doi: 10.1016/j.ijrobp.2008.06.1935

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 5 , Pages 1383-1390 , 1 April 2009

Article Tools

* Image Usage & Resolution